## HUM: Humana Inc. - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.00 indicates fundamental undervaluation. Consistent execution (3/4 quarters beat estimates).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($224.16)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 10
- **Sentiment:** Bullish (Bullish: 2, Bearish: 0)

**1. Humana Inc. (HUM) Reaffirms 2025 Earnings Guidance**
- Source: GuruFocus | 20251201T093000 | Bullish | Relevance: 99%
- Humana Inc. (HUM) has reaffirmed its earnings guidance for the fiscal year ending December 31, 2025, projecting a diluted EPS of approximately $12.26 and an adjusted EPS of approximately $17.00. The company's management will be engaging with investors and analysts throughout December to reiterate these projections, emphasizing confidence in its strategic direction and operational stability. Humana highlights that while Adjusted EPS is a key internal metric for performance and planning, it complements GAAP EPS and is not a substitute.

**2. New Insurance Coverage Resource Released by Muse Treatment Exploring Humana Inpatient Rehab Benefits**
- Source: The State Journal-Register | 20251202T080000 | Somewhat-Bullish | Relevance: 99%
- Muse Treatment has released a new educational resource detailing how Humana insurance covers inpatient rehabilitation for substance use disorders. This resource, available on their website, explains Humana's policies, medical necessity criteria, and verification procedures, aiming to provide clear, evidence-based information for patients and their families in Los Angeles. It emphasizes the importance of supervised detox and co-occurring disorder treatment, supporting informed decision-making for those seeking addiction recovery.

**3. New Insurance Coverage Resource Released by Muse Treatment Exploring Humana Inpatient Rehab Benefits**
- Source: The Herald-Mail | 20251202T080000 | Somewhat-Bullish | Relevance: 99%
- Muse Treatment has released a new educational resource detailing how Humana insurance covers inpatient rehab for substance-use disorders. This resource aims to provide neutral, evidence-supported explanations of Humana's policies, medical necessity criteria, and verification procedures to help patients understand their coverage options. The initiative aligns with Muse Treatment's mission to offer transparent, clinically-aligned information to individuals and families seeking addiction treatment.

**4. Humana Inc Reaffirms 2025 Earnings Guidance**
- Source: TradingView | 20251202T032530 | Bullish | Relevance: 99%
- Humana Inc. reaffirmed its 2025 earnings guidance during investor meetings on December 1, 2025. The company projected a reaffirmed FY 2025 EPS guidance of $12.26 and an adjusted EPS of $17.00. Potential changes are expected in GAAP EPS due to strategic initiatives.

**5. Hsbc Holdings PLC Decreases Stock Position in Humana Inc. $HUM**
- Source: MarketBeat | 20251201T094705 | Neutral | Relevance: 99%
- Hsbc Holdings PLC reduced its stake in Humana Inc. by 2.5% in the second quarter, selling 5,967 shares and holding 228,311 shares worth $55.67 million. While Hsbc decreased its position, other institutional investors like Vanguard Group Inc. and AQR Capital Management LLC significantly increased their holdings in Humana. The article also details Humana's recent earnings, dividend announcement, and various analyst ratings and price targets.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 1, Lowers: 1)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-05 | Jefferies | $313 | $253 | +24% |
| 2025-11-25 | Barclays | $234 | $245 | -4% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-05 | Jefferies | up | Buy |
| 2025-11-25 | Barclays | main | Equal-Weight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_BUYING** |
| Buys | 5 ($0.14M) |
| Sells | 0 ($0.00M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 57.3% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 5 / 5 |

**Top Holders:**
- Vanguard Group Inc: 11.8% (-0.3%)
- Dodge & Cox Inc.: 9.4% (-0.1%)
- JPMORGAN CHASE & CO: 8.4% (+237.0%)
- Blackrock Inc.: 8.3% (-3.0%)
- State Street Corpora: 4.5% (-0.2%)

### Key Risks

1. Long-term trend broken: trading 6.5% below SMA200.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.00 indicates undervaluation relative to growth. Balance sheet: strong liquidity (2.0x). Institutional flow bullish (5 buying vs 5 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $30.9B |
| Beta | 0.47 |
| 52W Range | $206.87 - $315.35 |
| Short Interest | 4.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.00 |
| Forward P/E | 19.2 |
| Current P/E | 14.2 |
| YoY Growth | -26.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 strengthening from -4.4% to -1.6% (+2.7% in 5 days), confirming momentum buildup. Below STRENGTH zone by 5.6pp (needs >4.0% for momentum thesis). Below SMA200 (0.94x), long-term trend not supportive. MACD histogram positive (2.06), confirming momentum. RSI neutral at 44.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -1.62% (CS: 39) | Neutral |
| RSI_14 | 44.0 | Neutral |
| MACD Histogram | 2.06 | Bullish |
| vs SMA20 | 1.001x | Above |
| vs SMA50 | 0.921x | Below |
| vs SMA200 | 0.935x | Below |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $241.96
- **Stop Loss:** $224.16 (7.4% risk)
- **Target:** $277.56 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 56
- **Position Value:** $13,549.76
- **Portfolio %:** 13.55%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-02-11 (Est: $-3.89)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.83 | $3.24 | +14.6% |
| 2025Q2 | $5.87 | $6.27 | +6.9% |
| 2025Q1 | $10.07 | $11.58 | +15.0% |
| 2024Q4 | $-2.12 | $-2.16 | -1.9% |

---
*RULE-based L3 | 2026-01-06 16:37 | MRS_20*